Does Wellcare Cover Orencia?
The verdict
Covered on most plans
Wellcare (Centene) covers Orencia for RA, PsA, and pJIA with prior authorization and step therapy across its Medicare Part D and Medicaid managed-care plans. The benefit depends on how Orencia is administered: SC (subcutaneous, self-injected) is a Part D specialty drug; IV infusion is a medical-benefit service billed under the medical benefit, with some state Medicaid programs (e.g., Texas) covering procedure code J0129. Orencia is typically a second-line biologic — step therapy through a preferred DMARD (adalimumab biosimilar or Enbrel) is required before approval. Medicaid cost-share is nominal; Medicare Part D coinsurance is capped at $2,100 in 2026.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Wellcare using your member ID.
Key facts
Orencia IV (abatacept infusion) is billed under HCPCS procedure code J0129 in some state Medicaid programs — for example, Texas Medicaid covers J0129 for psoriatic arthritis with a minimum age of 2 years.
Texas Medicaid preferred drug list / fee schedule; CMS HCPCS code J0129
Wellcare is operated by Centene, which manages Medicare Part D and Medicaid programs in many states — preferred-drug status for Orencia and step-therapy requirements vary by state PDL.
Centene Corporation coverage documentation; state Medicaid PDL resources
The 2026 Medicare Part D out-of-pocket cap of $2,100 applies to SC Orencia on the Part D specialty tier; IV Orencia is a Part B drug where the cap does not apply.
CMS 2026 Part D benefit parameters; Medicare Part B drug coverage guidance
Medicare vs. commercial coverage
Whether Wellcare covers Orencia depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare (operative pathway): SC Orencia is covered under Medicare Part D on the specialty tier — PA and step therapy required; 25–33% coinsurance after the deductible; the $2,100 (2026) Part D out-of-pocket cap limits annual exposure. Manufacturer copay assistance is NOT available to Medicare beneficiaries. IV Orencia is covered under Medicare Part B as a medical benefit — 20% Part B coinsurance after the deductible; on a Wellcare Medicare Advantage plan, the MA plan copay applies instead. Wellcare-managed Part D and MA plans follow Centene formulary and step-therapy requirements — verify on your specific Wellcare plan drug list.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: Wellcare has minimal commercial presence. Where commercial coverage exists, SC Orencia runs through the specialty-tier pharmacy benefit; IV Orencia runs through the medical benefit; PA and step therapy apply. ACA/Individual: limited Wellcare ACA presence; covered with PA where offered. Medicaid: Wellcare-managed Medicaid (Centene) covers Orencia per state preferred drug list with PA and step therapy; SC via specialty-pharmacy dispensing; IV abatacept billed under procedure code J0129 in some states — Texas Medicaid covers J0129 for PsA with an age limit of 2 years and older. Cost-share is nominal ($0–$4). Verify on your state Wellcare Medicaid drug list.
The 4 boxes you must tick to get approved
Commercial plans that will consider Orencia require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Orencia actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Orencia is a high-cost specialty biologic. Precise list-price figures were not available in our research — use your plan's formulary cost estimator or GoodRx for a current estimate. Cash costs vary significantly by form (SC vs. IV) and site of care.
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part D (SC): 25–33% coinsurance on the specialty tier after the deductible, capped by the $2,100 (2026) Part D OOP cap. Dual-eligible members — those enrolled in both Medicare and Medicaid — may have their Part D cost-share covered by Medicaid, often reducing out-of-pocket to $0. Medicare Part B (IV): 20% coinsurance after the Part B deductible; on a Wellcare MA plan, the MA copay applies. Medicaid (SC or IV): $0–$4 nominal cost-share; IV billed under J0129 in some states. Manufacturer copay assistance is NOT available to Medicare or Medicaid beneficiaries.
Typical monthly copay once prior authorization is approved.
Bridge program
Bristol Myers Squibb's Orencia Co-Pay Assistance Program may be available to commercially insured patients for SC Orencia. Medicare and Medicaid beneficiaries are NOT eligible. Verify eligibility directly with BMS.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Actual cost-share depends on your specific Wellcare plan and state PDL. Verify on your Wellcare plan drug list or by calling Wellcare member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Check your Wellcare plan drug list or state Medicaid PDL for abatacept/Orencia
Log in to your Wellcare member account or visit your state Medicaid preferred drug list to look up abatacept (Orencia). Confirm whether SC or IV is covered, at what tier, and what PA and step-therapy requirements apply. Because Centene operates Medicaid programs in many states, preferred-drug status and J-code billing for IV abatacept vary by state — confirm for your specific plan.
- 2
Discuss SC vs. IV form with your prescriber before submitting PA
The form your rheumatologist recommends affects which benefit rail is used and the PA process. SC (weekly self-injection) goes through Part D or the pharmacy benefit; IV infusion goes through the medical benefit and requires a clinic visit. Your prescriber should consider which form is clinically appropriate and which may have more favorable coverage or lower cost-share on your specific Wellcare plan.
- 3
Confirm dual-eligible cost-share if enrolled in both Medicare and Medicaid
If you are a Wellcare dual-eligible member (enrolled in both Medicare and Medicaid), your Medicaid plan may cover the Part D cost-share for SC Orencia or the Part B coinsurance for IV Orencia, potentially reducing your out-of-pocket cost to $0. Contact Wellcare member services to confirm your dual-eligible benefit structure and how cost-share is coordinated between Medicare and Medicaid.
Options if Wellcare won't cover Orencia
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Adalimumab biosimilar (Amjevita, Hyrimoz, or others)
Typically a required first-line step-therapy agent before Orencia for RA and PsA on Wellcare Part D and Medicaid plans. Pharmacy-benefit specialty drug with PA. Multiple FDA-approved adalimumab biosimilars are available; preferred product depends on the Wellcare/Centene formulary.
Enbrel (etanercept)
TNF inhibitor biologic DMARD; may be a required step-therapy agent before Orencia for RA, PsA, and ankylosing spondylitis. No marketed biosimilar until April 2029 (Erelzi/Eticovo blocked by patent litigation). Specialty tier with PA and step therapy on Wellcare plans.
Prolia (denosumab) / Jubbonti
Not an RA/PsA drug — Prolia is for osteoporosis. Noted here only for benefit-rail contrast: Wellcare Prolia is a fixed medical-benefit Part B q6-month injection; Wellcare Orencia SC is a Part D specialty drug (form-driven rail). Both require PA, but the benefit rail for Orencia is form-dependent, while for Prolia it is fixed.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Wellcare covers Orencia under both Part D and Part B depending on the form. SC (subcutaneous) Orencia is a Part D pharmacy-benefit specialty drug — PA required, 25–33% coinsurance, $2,100 (2026) cap. IV Orencia is a Part B medical-benefit service — 20% Part B coinsurance; Wellcare MA plan copay may apply. Confirm which form your prescriber intends with Wellcare before the PA is submitted.
J0129 is the HCPCS procedure code used to bill IV abatacept (Orencia) when administered in a clinic under the medical benefit. Texas Medicaid covers J0129 for psoriatic arthritis with an age requirement of 2 years and older. Wellcare-managed Medicaid in other states may have similar provisions — verify on your state's Medicaid preferred drug list or by contacting Wellcare Medicaid member services. IV billing under J0129 is separate from the Part D pharmacy benefit.
Yes. Wellcare Part D and Medicaid plans typically require documented trial and failure of preferred biologic DMARDs — usually an adalimumab biosimilar or Enbrel — before Orencia is approved for RA or PsA. Orencia is generally a second-line biologic. Your prescriber submits the PA with the required documentation of prior biologic treatment and clinical diagnosis. Verify the specific step-therapy sequence on your Wellcare plan.
For SC Orencia on Wellcare Part D, you pay 25–33% coinsurance on the specialty tier after the deductible, with the $2,100 (2026) annual cap limiting total exposure. For IV Orencia under Part B, you pay 20% of the Medicare-approved amount after the Part B deductible; on a Wellcare MA plan, your copay is per the MA plan design. Dual-eligible members may have Medicaid cover Part D or Part B cost-share, often reducing out-of-pocket to $0. Verify on your Wellcare plan documents.
Yes. Wellcare-managed Medicaid (Centene) covers abatacept/Orencia for approved indications per state preferred drug list, with prior authorization and step therapy required. SC is dispensed through a specialty pharmacy; IV may be billed under J0129 in states like Texas. Cost-share is nominal ($0–$4 per fill or administration). Because Centene manages Medicaid in many states, the specific PDL status and PA criteria vary — verify on your state's Wellcare Medicaid drug list.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Wellcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.